SRC and intrahepatic cholangiocarcinoma: In addition, Feng et al. in 2021 found that SRC + HIPEC improved median overall survival in patients with advanced intrahepatic cholangiocarcinoma (ICC) compared with SRC alone (25.53 vs. 11.17 months), although further prospective studies are needed.